Tripartite Therapeutics Inc. Share Price

Tripartite Therapeutics Inc is a Taiwan-based company mainly engaged in the development of hydrophilic platform technologies for antibody drug conjugate (ADC) and new drug research and development. It provides ADC design services and subsequent licensing through OmniLink linker technology and Polarpeutic hydrophilic payload modification technology. Its main product is the antibody polar drug conjugate (APDC) developed using the patented OmniLink technology. This APDC consists of the cytotoxic maytansinoid drug conjugated to the trastuzumab antibody. It is used for the drug treatment of various solid tumors such as breast cancer, lung cancer, and gastric cancer. It primarily provides products and services in Taiwan.